Mesothelioma Early Detection by VOCs

Identification of Biomarkers for the Early Detection of Mesothelioma

Status

Terminated

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04106973

Acronym

MED-VOC

Enrollment

Registered

2019-09-27

Start date

2019-06-05

Completion date

2022-01-01

Last updated

2026-08-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asbestos Exposure, Pleural Mesothelioma, Pleural Plaque

Keywords

Pleural Mesothelioma, Bilateral Pleural Plaques, Asbestos Exposure, Exhaled breath analysis, VOCs

Brief summary

This is a two phase study, The first phase (phase 1) will identify potential biomarkers among asbestos exposed individuals with pleural mesothelioma. The second phase (phase 2), is a double blinded case-matched controlled study to determine the predictive capability, sensitivity, and specificity of these biomarkers in detecting early stage pleural mesothelioma. Biomarkers in the form of volatile organic compounds (VOC) in exhaled breath samples from subjects with either pleural mesothelioma or pleural plaques, will be evaluated. A biomarker present in serum will also be concurrently evaluated in the same cohort. The soluble serum biomarker mesothelin related peptides (SMRP), which has been posited as a biomarker for mesothelioma, will be analyzed for its relationship to the breath VOC profile.

Detailed description

Mesothelioma is a rare, aggressive and treatment-resistant disease and, in the United States, is caused almost exclusively by exposure to asbestos fibers. There is often a lengthy latency period of 40-50 years between exposure and disease onset. The median age of diagnosis is 65 years while the median survival time after diagnosis of pleural mesothelioma without treatment is 9 months. Symptoms, where present, may be non-specific, which further contributes to delayed diagnosis. In this study, the volatile organic compound (VOC) profile of exhaled breath from subjects with histologically confirmed mesothelioma will be compared against case-matched control subjects with bilateral pleural plaques or bilateral pleural thickening. Putative markers will then be tested against a blinded cohort to test predictive value of the markers. This study seeks to identify markers for mesothelioma using a non-invasive technique which samples volatile organic compounds (VOC) in the breath of test subjects (Owlstone Medical Ltd, Cambridge, England). A comparison of the participant's VOC profile will be made with an FDA-approved, serum-based assay (Lumipulse Mesomark®, Fujirebio Diagnostics Inc., Malvern, PA) of the participant's soluble mesothelin related peptides (SMRP) to discern parameters of efficacy..

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Male or Female over 18 years of age * Clinical diagnosis of pleural mesothelioma or presence of pleural plaques on X-Ray * Documented exposure to asbestos * Must be able to provide breath sample * Must be able to provide relevant medical information

Exclusion criteria

* Presence of malignancies other that mesothelioma within the past 6 months * Treatment for any malignancies other than mesothelioma within the past 6 months * Inability to provide past clinical information * Inability to perform breath collection procedure * Smoking or consuming alcohol within two hours of conducting breath collection procedure

Design outcomes

Primary

Measure	Time frame	Description
VOC markers in breath samples. Predictive capability, sensitivity and specificity of biomarkers present in volatile organic compounds (VOC) for the early detection of pleural Mesothelioma in patients exposed to asbestos.	At study completion, approximately 2 years	Predictive capability, sensitivity and specificity of biomarkers present in volatile organic compounds (VOC) for the early detection of pleural Mesothelioma in patients exposed to asbestos.

Secondary

Measure	Time frame	Description
Predictive capability, sensitivity and specificity of Soluble Mesothelin Related Peptides (SMRP) in serum when combined with VOC biomarkers for pleural mesothelioma.	At study completion, approximately 2 years	Determine the additive predictive capability, sensitivity and specificity of SMRP serum biomarkers with VOC biomarkers for the early detection of pleural mesothelioma

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORMichael R Harbut, MD, MPH

Ascension Providence Hospital, Southfield

PRINCIPAL_INVESTIGATORDavid M Svinarich, PhD

Ascension Providence South East Michigan

Outcome results